Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company focused on the life sciences and healthcare sector, targeting businesses at the intersection of scientific research and commercial development. The SPAC filed a Form 425 with the SEC on July 28, 2026, signaling an active business combination process and placing the company in a late-stage deal phase. Form 425 filings are prospectus-related communications submitted in connection with a pending merger or acquisition transaction. TDAC's name reflects a thesis centered on translational medicine and biopharmaceutical development opportunities. For the full filing history, sponsor details, deal timeline, and target company data on TDAC, sign up for complete access at SpacDesk.